in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Hospira, PTI, Migenix and Shrink Nanotechnologies.
PTI has appointed Jesse Sklar as sales manager of its inspection systems division. Sklar has more than 17 years experience in pharma sales at companies including NJM/CLI, MAR srl and MG America.
Haibo Xu has resigned from his position as chief operating officer of Jiangbo Pharmaceuticals, citing health reasons. Jiangbo has begun searching for a replacement and Xu will continue as a member of the company’s board of directors.
Migenix has appointed Paul Brennan as CEO. Brennan has more than 20 years experience in pharma and biotech, most recently as CEO of Altair Therapeutics. He has also worked at Aspreva, AnorMED and spent more than 12 years at AstraZeneca.
Hoyoung Huh, president and CEO of BiPar Sciences, has been appointed as chairman of Epizyme’s board of directors. Huh led BiPar’s $500m (€336m) merger with Sanofi-Aventis and during his time at Nektar Therapeutics was involved in numerous partnerships with big pharma.
Hospira has named Daphne Jones as senior vice president (VP) and chief information officer. In this capacity Jones will be responsible for Hospira’s IT systems and executing its global strategies in this area. Most recently Jones worked at Johnson & Johnson.
Steven Kafka has been appointed as chief financial officer and VP, finance and operations at Aileron Therapeutics. Kafka has more than 12 years experience in the sector at companies including Infinity Pharmaceuticals, Millennium Pharmaceuticals and Strategic Decisions Group.
Shrink Nanotechnologies has appointed Bruce Conklin and Kara McCloskey to its scientific advisory board. Conklin has expertise in induced-pluripotent stem (iPS) cells and McCloskey has experience of tissue engineering.